Zymeworks to acquire Theravance Biopharma for $929M, gaining rights to COPD drug Yupelri's US profit share and ex-US royalties generating ~$60M annually.
Zymeworks is set to put Theravance Biopharma out of its misery, announcing on Monday that it will buy the biotech for $929 million upfront in …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Zymeworks Targets Long-Term Cash Generation Through Theravance Acquisition - Theravance Biopharma (NASDAQ
Zymeworks acquires struggling Theravance for $929M
Theravance, after clinical setbacks, agrees to $929M buyout
THERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT VALUE RIGHT
Remix to go public in reverse merger with once high-flying Passage Bio
Merck KGaA Swoops In With $11.3 Billion Medtech Buyout
Antares gets $105M from Novartis for new cancer drugs
Zymeworks will acquire Theravance Biopharma for $929 million, adding YUPELRI cash flows and expanding its portfolio.
Four months after Theravance Biopharma shut down its R&D unit, laid | Four months after Theravance Biopharma shut down its R&D…
The acquisition by royalty management company Zymeworks follows a "strategic review" triggered by the failure of a drug for a…
THERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT…
The data showed that del-brax, an “antisense oligonucleotide conjugate” being tested against a muscle-wasting disease, met its…
The deal bolsters AbbVie's immunology and inflammation pipeline, answering a key investor question about what comes after Skyrizi.
